Use of a Chinese medicine composition in treating Alzheimer's disease

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition having the effect of improving or treating dementia. The traditional Chinese medicine composition is mainly prepared from Notopterygium wilfordii, Angelica dahurica, Poria cocos, Saposhnikovia divaricata, Nepeta tenuifolia, Rhizoma Chuanxiong, Platycodon grandiflorum, Radix Bupleuri, Peucedanum peucedanum, Fructus aurantii and Radix Glycyrrhizae. Pharmacological experiments have confirmed that the Jingfang granules prepared from the traditional Chinese medicine composition of the present invention can improve the learning and memory ability of mice with Alzheimer's disease by increasing the content of monoamine neurotransmitters.

Description

Technical Field

[0001] The invention relates to a composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for treating senile dementia, belonging to the technical field of traditional Chinese medicine. Background Art

[0002] In a broad sense, all dementia symptoms that occur in the elderly (generally refers to those over 60 years old in China) can be called senile dementia, such as vascular dementia, frontotemporal dementia, Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, etc. However, senile dementia in medicine usually refers specifically to Alzheimer's disease, which is a neurodegenerative disease with insidious onset and progressive development. Patients may have clinical manifestations such as memory impairment, aphasia, apraxia, agnosia, visual-spatial ability impairment, impaired abstract thinking and calculation ability, personality and behavioral changes, etc. At present, there are many types of drugs used in clinical treatment of this disease, but there is no drug that can reverse cognitive impairment.

[0003] The World Health Organization (WHO) estimates that the prevalence of Alzheimer's disease in the global population over 65 years old is 4% to 7%. In China, the prevalence of Alzheimer's disease in the population over 65 years old is 4.2% in the north and 2.8% in the south.

[0004] Typical symptoms of Alzheimer's disease are:

[0005] 1. Pre-dementia stage

[0006] Patients at this stage may have no cognitive impairment or only mild impairment, mainly manifested by mild impairment of memory, decreased ability to learn and retain new knowledge, and mild impairment of other cognitive domains, such as attention, executive ability, language ability, and visual-spatial ability, but it does not affect basic daily living ability and does not reach the level of dementia.

[0007] 2. Dementia stage

[0008] This stage can be divided into three levels according to the degree of cognitive impairment:

[0009] (1) Mild: The main manifestation is memory impairment. The first thing that appears is the loss of recent memory, and people often forget what they do in daily life and some commonly used items. As the disease progresses, long-term memory loss may occur, that is, forgetting things and people that happened a long time ago. Some patients have visual-spatial disorders, cannot find the way home after going out, and cannot accurately copy three-dimensional pictures. When faced with unfamiliar and complex things, they are prone to fatigue, anxiety and negative emotions, and may also show personality disorders, such as not liking to clean, slovenly, irritable, angry, selfish and suspicious.

[0010] (2) Moderate: In addition to the continued aggravation of memory impairment, the ability to work, learn new knowledge and social contact is reduced, especially the knowledge and skills that have been mastered show a significant decline. There is a decline in logical thinking and comprehensive analysis ability, repeated speech, decreased calculation ability, obvious visual-spatial disorders, such as being unable to find one's own room at home, and aphasia, apraxia, agnosia, etc. Some patients may also have epilepsy and tonic-hypokinetic syndrome. At this time, patients often have more obvious behavioral and mental abnormalities. Introverted patients become irritable, excited and euphoric, and talk more, while patients with extroverted personalities may become silent and uninterested in anything, show obvious personality changes, and even do some behaviors that lose their sense of shame (such as urinating and defecating anywhere).

[0011] (3) Severe: In addition to the gradual aggravation of the above symptoms, patients at this stage also experience emotional indifference, erratic crying and laughing, loss of speech ability, and inability to complete simple daily life tasks such as dressing and eating. They stay in bed all day without speaking, and gradually lose the ability to contact the outside world (including relatives and friends). The limbs become rigid or flexed and paralyzed, and the sphincter function is impaired. In addition, patients at this stage often have symptoms of systemic diseases, such as lung and urinary tract infections, pressure sores, and systemic failure symptoms, and eventually die from complications. Summary of the invention

[0012] The main purpose of the present invention is to provide a traditional Chinese medicine composition with the effect of improving or treating Alzheimer's disease. The traditional Chinese medicine composition is mainly prepared from Notopterygium wilfordii, Angelica dahurica, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Chuanxiong, Platycodon grandiflorum, Bupleurum chinense, Peucedanum peucedanum, Fructus aurantii and Licorice.

[0013] The present invention is a further development of the use of the existing product "Jingfang Granules". The new use of Jingfang Granules for hangover relief comes from feedback from company employees. Company employees reported that family members with Alzheimer's disease have been taking Jingfang Granules for a long time to prevent colds. After taking Jingfang Granules for nearly half a year, employees found that their family members' memory ability has improved slightly compared to before. Based on the feedback from use, the inventor further studied and developed the new use of Jingfang Granules and its formula for "improving or treating Alzheimer's disease".

[0014] One of the purposes of the present invention is to provide the specific composition of the above-mentioned Chinese medicine composition, that is, the Chinese medicine composition is mainly prepared from the following raw materials:

[0015]

[0016] Preferably, the Chinese medicine composition is mainly prepared from the following raw materials:

[0017]

[0018]

[0019] Further preferably, the Chinese medicine composition is mainly prepared from the following raw materials:

[0020]

[0021] The second object of the present invention is to provide a method for preparing the above-mentioned Chinese medicine composition, which mainly comprises the following steps:

[0022] Step A: distill and extract volatile oil from Nepeta tenuifolia, Saposhnikovia divaricata, Notopterygium wilfordii, Angelica pubescens, Peucedanum chinense, Rhizoma Chuanxiong and Fructus Aurantii Immaturus for later use, and keep the residues after distillation and the aqueous solution of Rhizoma Chuanxiong and Fructus Aurantii Immaturus for later use;

[0023] Step B: preparing a 10-40% ethanol solution with the distilled Chuanxiong and Citrus aurantium aqueous solution obtained in step A for later use;

[0024] Step C: Mix the Poria cocos, the distilled Chuanxiong Rhizoma and the Fructus Aurantii Immaturus residues obtained in step A, and extract by percolation with the ethanol solution obtained in step B, and set aside the percolation solution;

[0025] Step D: adding water to bupleurum, platycodon, liquorice, and the distilled schizonepeta, siler, notopterygium, angelica pubescens, and peucedanum chinense residues obtained in step A and decocting the decoction, and concentrating the decoction for later use;

[0026] Step E: the percolate obtained in step C and the decoction obtained in step D are mixed, concentrated, and the volatile oil obtained in step A is added to obtain the product.

[0027] Preferably, the preparation method mainly comprises the following steps:

[0028] Step A: distill and extract volatile oil from Nepeta tenuifolia, Saposhnikovia divaricata, Notopterygium wilfordii, Angelica pubescens, Peucedanum chinense, Rhizoma Chuanxiong and Fructus Aurantii Immaturus for later use, and keep the residues after distillation and the aqueous solution of Rhizoma Chuanxiong and Fructus Aurantii Immaturus for later use;

[0029] Step B: preparing a 15-30% ethanol solution with the distilled Chuanxiong and Citrus aurantium aqueous solution obtained in step A for later use;

[0030] Step C: Mix the Poria cocos, the distilled Chuanxiong Rhizoma and the Fructus Aurantii Immaturus residues obtained in step A, and extract by percolation with the ethanol solution obtained in step B, and set aside the percolation solution;

[0031] Step D: adding water to bupleurum, platycodon, liquorice, and the distilled schizonepeta, siler, notopterygium, angelica pubescens, and peucedanum hupensis residues obtained in step A and decocting the decoction into a thick paste for later use;

[0032] Step E: Mix the percolate obtained in step C and the thick paste obtained in step D, concentrate them into a clear paste, add the volatile oil obtained in step A, and obtain the product.

[0033] Further preferably, the preparation method mainly comprises the following steps:

[0034] Step A: distill and extract volatile oil from Nepeta tenuifolia, Saposhnikovia divaricata, Notopterygium wilfordii, Angelica pubescens, Peucedanum chinense, Rhizoma Chuanxiong and Fructus Aurantii Immaturus for later use, and keep the residues after distillation and the aqueous solution of Rhizoma Chuanxiong and Fructus Aurantii Immaturus for later use;

[0035] Step B: preparing a 25% ethanol solution with the distilled Chuanxiong and Fructus Aurantii Immaturus aqueous solution obtained in step A for later use;

[0036] Step C: Mix the Poria cocos, the distilled Chuanxiong Rhizoma and the Fructus Aurantii Immaturus residues obtained in step A, and extract by percolation with the ethanol solution obtained in step B, and set aside the percolation solution;

[0037] Step D: adding water to bupleurum, platycodon, liquorice, and the distilled schizonepeta, siler, notopterygium, angelica pubescens, and peucedanum hupensis residues obtained in step A and decocting the decoction into a thick paste for later use;

[0038] Step E: Mix the percolate obtained in step C and the thick paste obtained in step D, concentrate them into a clear paste, add the volatile oil obtained in step A, and obtain the product.

[0039] The third object of the present invention is to provide a Chinese medicine preparation containing the above-mentioned Chinese medicine composition or mainly prepared from the above-mentioned Chinese medicine composition, and the Chinese medicine preparation can be a clinically acceptable oral preparation.

[0040] Preferably, the oral preparation may be a solid preparation and / or a liquid preparation.

[0041] Further preferably, the liquid preparation includes but is not limited to oral liquid, suspension, syrup, mixture, the solid includes but is not limited to tablets, pills, powders, granules, capsules, and the gas preparation is an aerosol or inhalant;

[0042] More preferably, the liquid preparation is a mixture, and the solid preparation is a granule.

[0043] Compared with the prior art, the present invention has achieved remarkable technical effects:

[0044] Pharmacological experiments have confirmed that the Jingfang granules prepared from the Chinese medicine composition of the present invention can significantly improve the learning and memory ability of Alzheimer's disease model mice caused by aluminum chloride, and can significantly increase the NE, DA, and 5-HT contents in the brain tissue of the model mice, indicating that the Jingfang granules can improve the learning and memory ability of Alzheimer's disease mice by increasing the content of monoamine neurotransmitters. DETAILED DESCRIPTION

[0045] Example 1 Granule Preparation

[0046] prescription:

[0047] Schizonepeta 75g, Saposhnikovia 75g, Notopterygium 75g, Angelica dahurica 75g, Bupleurum 75g, Peucedanum 75g, Ligusticum chuanxiong 75g, Citrus aurantium 75g, Poria 75g, Platycodon 75g, Licorice 25g;

[0048] Preparation method:

[0049] Step A: distill and extract volatile oil from Schizonepeta, Saposhnikovia divaricata, Notopterygium wilfordii, Angelica pubescens, Peucedanum chinense, Ligusticum chuanxiong and Fructus Aurantii Immaturus respectively for later use, and keep the residues after distillation and the aqueous solution of Ligusticum chuanxiong and Fructus Aurantii Immaturus for later use;

[0050] Step B: preparing a 25% ethanol solution with the distilled Chuanxiong and Fructus Aurantii Immaturus aqueous solution obtained in step A for later use;

[0051] Step C: Mix the Poria cocos, the distilled Chuanxiong Rhizoma and the Fructus Aurantii Immaturus residues obtained in step A, and extract by percolation with the ethanol solution obtained in step B, and set aside the percolation solution;

[0052] Step D: decocting the radix bupleuri, platycodon grandiflorum, liquorice, and the distilled schizonepeta, siler, notopterygium wilfordii, angelica pubescens, and peucedanum chinense residues obtained in step A with water for two times, each time for 1.5 hours, combining the two decoctions, filtering, and concentrating into a thick paste for later use;

[0053] Step E: Mix the percolate obtained in step C and the thick paste obtained in step D, let stand, filter and concentrate into a clear paste, add an appropriate amount of sucrose, mix well, make granules, dry, add the volatile oil obtained in step A, mix well, and obtain the product.

[0054] Example 2 Granule Preparation

[0055] prescription:

[0056] Schizonepeta 70g, Saposhnikovia 85g, Notopterygium wilfordii 60g, Angelica pubescens 90g, Bupleurum 70g, Peucedanum 90g, Ligusticum chuanxiong 70g, Fructus aurantii 80g, Poria 50g, Platycodon grandiflorum 80g, Licorice root 20g;

[0057] The preparation method is similar to that of Example 1.

[0058] Example 3 Granule Preparation

[0059] prescription:

[0060] Schizonepeta 60g, Saposhnikovia 90g, Notopterygium 50g, Angelica dahurica 110g, Bupleurum 60g, Peucedanum 100g, Ligusticum chuanxiong 60g, Fructus aurantii 100g, Poria 50g, Platycodon 80g, Licorice 20g;

[0061] The preparation method is similar to that of Example 1.

[0062] Example 4 Preparation of mixture

[0063] prescription:

[0064] Schizonepeta 97g, Saposhnikovia 97g, Notopterygium 97g, Angelica dahurica 97g, Bupleurum 97g, Peucedanum 97g, Ligusticum chuanxiong 97g, Citrus aurantium 97g, Poria 97g, Platycodon 97g, Licorice 32.4g;

[0065] Preparation method:

[0066] Step A: distill and extract volatile oil from Schizonepeta, Saposhnikovia divaricata, Notopterygium wilfordii, Angelica pubescens, Peucedanum chinense, Ligusticum chuanxiong and Fructus Aurantii Immaturus respectively for later use, and keep the residues after distillation and the aqueous solution of Ligusticum chuanxiong and Fructus Aurantii Immaturus for later use;

[0067] Step B: preparing a 25% ethanol solution with the distilled Chuanxiong and Fructus Aurantii Immaturus aqueous solution obtained in step A for later use;

[0068] Step C: Mix the Poria cocos, the distilled Chuanxiong Rhizoma and the Fructus Aurantii Immaturus residues obtained in step A, and extract by percolation with the ethanol solution obtained in step B, and set aside the percolation solution;

[0069] Step D: Add water to bupleurum, platycodon, liquorice, and the distilled schizonepeta, siler, notopterygium, angelica dahurica, and peucedanum huo residues obtained in step A and decoct three times, combine the decoctions, filter, and concentrate to about 1300 ml for later use;

[0070] Step E: Mix the percolate obtained in step C and the concentrated decoction obtained in step D, let stand, filter and concentrate to about 1000 ml, add appropriate amount of sodium benzoate and volatile oil obtained in step A, mix well, and add water to 1000 ml to obtain the product.

[0071] Example 5 Preparation of mixture

[0072] prescription:

[0073] Schizonepeta 85g, Saposhnikovia 70g, Notopterygium wilfordii 90g, Angelica dahurica 60g, Bupleurum 90g, Peucedanum 70g, Ligusticum chuanxiong 90g, Citrus aurantium 50g, Poria 80g, Platycodon grandiflorum 70g, Licorice root 30g;

[0074] The preparation method is similar to that of Example 4.

[0075] Example 6 Preparation of mixture

[0076] prescription:

[0077] Schizonepeta 90g, Saposhnikovia 60g, Notopterygium 110g, Angelica dahurica 50g, Bupleurum 100g, Peucedanum 60g, Ligusticum chuanxiong 120g, Citrus aurantium 50g, Poria 100g, Platycodon 70g, Licorice 30g;

[0078] The preparation method is similar to that of Example 4.

[0079] Example 7 Syrup Preparation

[0080] prescription:

[0081] Schizonepeta 75g, Saposhnikovia 75g, Notopterygium 75g, Angelica dahurica 75g, Bupleurum 75g, Peucedanum 75g, Ligusticum chuanxiong 75g, Citrus aurantium 75g, Poria 75g, Platycodon 75g, Licorice 25g;

[0082] Preparation method Referring to Example 4, syrup was prepared according to conventional process.

[0083] Example 8 Oral Liquid Preparation

[0084] prescription:

[0085] Schizonepeta 97g, Saposhnikovia 97g, Notopterygium 97g, Angelica dahurica 97g, Bupleurum 97g, Peucedanum 97g, Ligusticum chuanxiong 97g, Citrus aurantium 97g, Poria 97g, Platycodon 97g, Licorice 32.4g;

[0086] Preparation method Referring to Example 4, the oral liquid was prepared according to conventional process.

[0087] Example 9 Tablet Preparation

[0088] prescription:

[0089] Schizonepeta 75g, Saposhnikovia 75g, Notopterygium 75g, Angelica dahurica 75g, Bupleurum 75g, Peucedanum 75g, Ligusticum chuanxiong 75g, Citrus aurantium 75g, Poria 75g, Platycodon 75g, Licorice 25g;

[0090] Preparation Method Referring to Example 1, tablets were prepared according to conventional techniques.

[0091] Example 10 Capsule Preparation

[0092] prescription:

[0093] Schizonepeta 75g, Saposhnikovia 75g, Notopterygium 75g, Angelica dahurica 75g, Bupleurum 75g, Peucedanum 75g, Ligusticum chuanxiong 75g, Citrus aurantium 75g, Poria 75g, Platycodon 75g, Licorice 25g;

[0094] Preparation method: Refer to Example 1 and prepare capsules according to conventional technology.

[0095] Example 11 Pill Preparation

[0096] prescription:

[0097] Schizonepeta 75g, Saposhnikovia 75g, Notopterygium 75g, Angelica dahurica 75g, Bupleurum 75g, Peucedanum 75g, Ligusticum chuanxiong 75g, Citrus aurantium 75g, Poria 75g, Platycodon 75g, Licorice 25g;

[0098] Preparation method: Refer to Example 1 and prepare pills according to conventional technology.

[0099] 2. Pharmacological Experiments

[0100] In order to verify the efficacy of the Chinese medicine composition of the present invention in improving or treating Alzheimer's disease, the inventors conducted relevant pharmacodynamics experiments. It should be noted that the drugs selected for the following pharmacodynamics experiments are drugs obtained from the representative formulas and preparation methods of the present invention; the inventors also conducted pharmacodynamics experiments on drugs obtained from other formulas and preparation methods included in the present invention, and the experimental results showed that the drugs obtained from other formulas and preparation methods have the same or similar effects, but due to space limitations, they are not listed here one by one; in addition, the following pharmacodynamics experiments only use some representative animal models as examples to verify the efficacy of the present invention.

[0101] The inventors would like to explain that the following experimental studies were conducted on the basis of the acute toxicity test and the long-term toxicity test to prove the safety of the drug, and the dosages used in the experimental studies were all within the safe dosage range.

[0102] The composition of the present invention improves the learning and memory ability of Alzheimer's disease mice induced by aluminum oxide

[0103] 1 Materials

[0104] 1.1 Animals:

[0105] Kunming mice, SPF grade, 30-35 g, experimental animal license number: SYXK(Lu)2018 0008, were provided by Lunan Pharmaceutical Group Co., Ltd. and were adaptively raised for one week before the experiment.

[0106] 1.2 Drugs and reagents

[0107] 1.2.1 Drugs

[0108] The granules obtained in Examples 1, 2, and 3 of the present invention, and the mixture obtained in Example 4;

[0109] Piracetam tablets (National Medicine Approval No. H22023211)

[0110] 1.2.3 Dosage for mice

[0111] Example 1 Granules: 2.925 g / kg (low dose), 5.85 g / kg (medium dose), 11.7 g / kg (high dose);

[0112] Example 2 Granules: 5.85 g / kg;

[0113] Example 3 Granules: 5.85 g / kg;

[0114] Embodiment 4 mixture: 8.0ml / kg;

[0115] Piracetam tablets: 0.64g / kg.

[0116] 2. Experimental Procedure

[0117] 2.1 Animal grouping, modeling and drug administration

[0118] 90 mice were randomly divided into blank group, model group, piracetam tablet group, three dosage groups of Example 1 (high, medium and low), Example 2 group, Example 3 group and Example 4 group, a total of 9 groups, 10 mice in each group. Except for the blank group, which was given normal saline by gavage, the other groups of mice were given aluminum chloride (200 mg / kg) by gavage every day to establish an Alzheimer's disease model, and the modeling was continued for 50 days; after the mice were given aluminum chloride by gavage, the mice in each administration group were given corresponding drugs by gavage, and the model group and the blank group were given an equal amount of normal saline by gavage, and the drug was continuously administered for 60 days.

[0119] 2.2 Index determination

[0120] 2.2.1 Learning and memory ability assessment

[0121] The Morris water maze method was used for determination. The water depth was 20 cm and the platform was 1 cm above the platform. Starting from the 56th day of drug administration, the mice were put into the water 1 hour after the last drug administration, and the time required for the mice to climb onto the platform from entering the water was recorded. The training test was continued for 4 days, 2 times / day, and each test was 60 s. If the platform was not found within 60 s, the escape latency was recorded as 60 s, and the mice were led to stay on the platform for 20 s. On the 5th day, the platform was removed, and the same entry point was selected to record the swimming trajectory of the mice within 60 s, the time they stayed in the quadrant of the original platform, and the number of times they crossed the platform.

[0122] 2.2.2 Determination of NE (norepinephrine), DA (dopamine), and 5-HT (5-hydroxytryptamine) contents in brain tissue

[0123] After the memory ability test of mice was completed, the mice were fasted for 24 hours, decapitated, and the brain tissue was removed. The contents of NE, DA, and 5-HT in the brain tissue were determined by high performance liquid chromatography-electrochemical method.

[0124] 2.3 Statistical analysis

[0125] SPSS 22.0 software was used to analyze the data. The differences were statistically significant when P < 0.05.

[0126] 3. Results and Conclusions

[0127] 3.1 Detection of learning and memory ability of mice in each group

[0128] Compared with the blank group, the escape latency of mice in the model group was significantly prolonged, and the number of crossings was significantly reduced (P < 0.01); compared with the model group, the escape latency of mice in each drug-treated group was significantly shortened, and the number of crossings was significantly increased (P < 0.05 or P < 0.01); the escape latency and number of crossings of mice in the individual embodiment groups of the present invention were not different from those of the piracetam tablets group (P > 0.05). The results are shown in Table 1.

[0129] Table 1 Comparison of escape latency and crossing times of mice in each group

[0130]

[0131]

[0132] Note: Compared with the blank group, * P<0.05, △ P < 0.01;

[0133] Compared with the model group, # P < 0.01;

[0134] Compared with the piracetam group, & P<0.05.

[0135] 3.2 Results of determination of NE, DA and 5-HT contents in brain tissue of mice in each group

[0136] Compared with the blank group, the contents of NE, DA, and 5-HT in the brain tissue of mice in the model group were significantly reduced (P < 0.01); compared with the model group, the contents of NE, DA, and 5-HT in the brain tissue of mice in each drug-treated group were significantly increased (P < 0.01); the contents of NE, DA, and 5-HT in the brain tissue of mice in the individual embodiment groups of the present invention were not different from those in the piracetam tablets group (P > 0.05). The results are shown in Table 2.

[0137] Table 2 Comparison of NE, DA and 5-HT contents in brain tissue of mice in each group

[0138]

[0139] Note: Compared with the blank group, * P<0.05, △ P < 0.01;

[0140] Compared with the model group, # P < 0.01;

[0141] Compared with the piracetam group, & P<0.05.

Claims

1. A use of a traditional Chinese medicine composition prepared by 50-110 parts by weight of Notopterygium wilfordii, 50-110 parts by weight of Angelica dahurica, 50-100 parts by weight of Poria cocos, 60-90 parts by weight of Saposhnikovia divaricata, 60-90 parts by weight of Schizonepeta tenuifolia, 60-120 parts by weight of Ligusticum chuanxiong, 70-80 parts by weight of Platycodon grandiflorum, 60-100 parts by weight of Bupleurum chinense, 60-100 parts by weight of Peucedanum peucedanum, 50-100 parts by weight of Fructus aurantii and 20-30 parts by weight of Liquorice in preparing a drug for improving and / or treating Alzheimer's disease.

2. The use according to claim 1, characterized in that The Chinese medicine composition is prepared from the following raw materials: Nepeta 70-85 weight parts Saposhnikovia 70-85 weight parts Notopterygium 60-90 weight parts Angelica dahurica 60-90 weight parts Bupleurum 70-90 weight parts Peucedanum peucedanum 70-90 weight parts Chuanxiong 70-90 weight parts Citrus aurantium 50-80 weight parts Poria 50-80 weight parts Platycodon grandiflorum 70-80 parts by weight; Licorice 20-30 parts by weight.

3. The use according to claim 2, characterized in that The Chinese medicine composition is prepared from the following raw materials: 75 weight parts of Schizonepeta tenuifolia 75 weight parts of Saposhnikovia divaricata 75 weight parts of Notopterygium incisum 75 weight parts Angelica dahurica 75 weight parts Bupleurum 75 weight parts Peucedanum peucedanum 75 weight parts Chuanxiong 75 weight parts Citrus aurantium 75 weight parts Poria 75 weight parts 75 parts by weight of Platycodon grandiflorum and 25 parts by weight of Licorice.

4. The use according to any one of claims 1 to 3, characterized in that The Chinese medicine composition is prepared into a clinically accepted Chinese medicine preparation.

5. The use according to claim 4, characterized in that The Chinese medicine preparation is an oral preparation or other preparations.

6. The use according to claim 5, characterized in that The oral preparation is a solid preparation and / or a liquid preparation.

7. The use according to claim 6, characterized in that The liquid preparations are oral liquids, suspensions, syrups, and mixtures, and the solid preparations are tablets, pills, powders, granules, and capsules.

8. The use according to claim 7, characterized in that The liquid preparation is a mixture, and the solid preparation is a granule.

Images